Orca-T not checked

Orca Biosystems, Inc.

FollowEvery change as it happens, and a Monday email
Next date
Phase 2 trial completes
Trials
3 active
3 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Acute Myeloid Leukemia (2 trials), Acute Lymphoid Leukemia (2 trials), Mixed Phenotype Acute Leukemia (2 trials), Acute Leukemia (2 trials), Myelodysplastic Syndromes (2 trials), Undifferentiated Leukemia, Myelodysplastic Syndrome, Therapy-Related Myelodysplastic Syndrome and 3 more
Main trialPhase 3
“This study will evaluate the safety, tolerability, and efficacy of Orca-T, an allogeneic stem cell and T-cell immunotherapy biologic manufactured for each patient (transplant recipient) from the mobilized peripheral blood of a specific, unique donor. It is composed of purified hematopoietic stem and progenitor cells (HSPCs), purified regulatory T cells (Tregs), and conventional T cells (Tcons) in participants undergoing myeloablative allogeneic hematopoietic cell transplant transplantation for hematologic malignancies. This posting represents the Phase III component of Precision-T. The…”In the company’s words, NCT05316701 on ClinicalTrials.gov

Other drugs for Acute Myeloid Leukemia

All 140 drugs for Acute Myeloid Leukemia

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 15 Jul 2024 Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Phase 2Recruiting Nov 2027 Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase 1Active, not recruiting 30 Apr 2025 Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Orca-T

Following is part of Solo: you see every change to Orca-T the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in